

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2696)**

## **VOLUNTARY ANNOUNCEMENT**

### **APPLICATION FOR CLINICAL TRIAL OF HLX6018 (RECOMBINANT ANTI-GARP/TGF- $\beta$ 1 HUMANISED MONOCLONAL ANTIBODY INJECTION) WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

#### **A. INTRODUCTION**

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that, recently, application for clinical trial of HLX6018 (recombinant anti-GARP/TGF- $\beta$ 1 humanised monoclonal antibody injection) (“**HLX6018**”) independently developed by the Company was approved by the National Medical Products Administration.

#### **B. ABOUT HLX6018**

HLX6018 is an innovative anti-GARP/TGF- $\beta$ 1 complex monoclonal antibody independently developed by the Company, which is intended to be used for the treatment of fibrosis-related diseases. Glycoprotein A Reiterations Predominant (GARP) is a Type I transmembrane cell surface docking receptor for latent transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1). The complex formed by GARP binding with latent TGF- $\beta$ 1 triggers structural changes by binding with integrins or cleavage by thrombin, releasing mature TGF- $\beta$ 1. HLX6018 can inhibit the release of mature TGF- $\beta$ 1 by specifically binding to the GARP/TGF- $\beta$ 1 complex, subsequently suppressing the TGF- $\beta$ 1-mediated activation, proliferation, and extracellular matrix secretion of fibroblasts to achieve the purpose of treating fibrosis-related diseases. Non-clinical studies have shown that HLX6018 has significant anti-pulmonary fibrosis and renal fibrosis effects and has a favorable safety profile.

## C. MARKET CONDITION

As of the date of this announcement, no monoclonal antibody targeting GARP/TGF- $\beta$ 1 has been approved for marketing globally.

**WARNING STATEMENT WITH REFERENCE TO THE REQUIREMENTS UNDER RULE 18A.05 OF THE RULES GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED:** The Company cannot guarantee the successful development and commercialization of HLX6018. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 12 March 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*